Megestrol Acetate / Acetato de megestrol 160mg
Product Overview
| Generic Name | Megestrol Acetate / Acetato de megestrol 160mg |
| Brand Name(s) | Megace® |
| Category | Antineoplastic / Cancer |
| Form | 30 Oral Tablets |
| Strength | 160 mg per tab |
| Therapeutic Class | Synthetic progestin; antineoplastic hormonal agent; progesterone derivative |
| ATC Code | L02AB01 |
Manufacturing & Regulatory
| Manufacturer | Bausch Ireland, Biogen |
| GMP Compliance | WHO-GMP |
| COFEPRIS | 010.000.5430.00 (40mg) |
| Free Sale Certificate | Yes, available as COPP/CPP |
Logistics & Export
| MOQ | 10 Units |
| Shelf Life | 36 months |
| Storage | store at or below 25°C / controlled room temperature |
| Incoterms | EXW, HS/HSN 30049099 |
| Lead Time | 7 - 10 Business Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Supplied per batch upon request |
| CTD Summary (PDF) | CTD proprietary; available under commercial agreement/license |
Special Notes
Megestrol acetate 160 mg tablets are oral synthetic progestin therapy used in specialist oncology settings for palliative management of advanced breast cancer and endometrial carcinoma. Megestrol is also used in selected formulations and clinical contexts as an appetite stimulant for anorexia/cachexia or significant weight loss, particularly in AIDS- or cancer-associated wasting.